| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom
Purpose: The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes involved in tumor invasion; several individual members of which have been implicated in tumor prognosis. These enzymes and their physiologic inhibitors, the tissue inhibitors of matrix metalloproteinases (TIMPs), act in a coordinated manner to form an integrated system. Therefore, to understand their role in tumor invasion, it is necessary to evaluate them collectively.
Experimental Design: In this study all of the major members of the matrix metalloproteinase (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MT1-MMP and MT2-MMP)/tissue inhibitor of matrix metalloproteinase (TIMP-1, TIMP-2, and TIMP-3) system have been investigated by immunohistochemistry in a series (n = 90) of stage III (Dukes’ C) colorectal cancers. An immunohistochemical score based on the intensity of immunoreactivity and proportion of immunoreactive cells was established for each MMP and TIMP.
Results: The MMP/TIMP profile defined by hierarchical cluster analysis of the immunohistochemical score identifies a distinct group of colorectal cancers with poor prognosis (log-rank test, 12.22, P = 0.0005). The median survival time of patients in this survival group was 18 months compared with a median survival of 49 months in the "good" survival group. Multivariate analysis showed that this profile was independently the most significant prognostic factor (P = 0.001).
Conclusions: This study has identified that the MMP/TIMP profile is an independent indicator of poor prognosis in colorectal cancer.
This article has been cited by other articles:
|
|
 |
|
  R. Gallego, J. Codony-Servat, X. Garcia-Albeniz, E. Carcereny, R. Longaron, A. Oliveras, M. Tosca, J. M. Auge, P. Gascon, and J. Maurel Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer Endocr. Relat. Cancer, March 1, 2009; 16(1): 311 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. GENTNER, A. WEIN, R. S. CRONER, I. ZEITTRAEGER, R. M. WIRTZ, F. ROEDEL, A. DIMMLER, L. DORLAQUE, W. HOHENBERGER, E. G. HAHN, et al. Differences in the Gene Expression Profile of Matrix Metalloproteinases (MMPs) and their Inhibitors (TIMPs) in Primary Colorectal Tumors and their Synchronous Liver Metastases Anticancer Res, January 1, 2009; 29(1): 67 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. FREDERIKSEN, A.F. LOMHOLT, G.J. DAVIS, B.L. DOWELL, M.A. BLANKENSTEIN, I.J. CHRISTENSEN, N. BRUNNER, and H.J. NIELSEN Changes in Plasma TIMP-1 Levels after Resection for Primary Colorectal Cancer Anticancer Res, January 1, 2009; 29(1): 75 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer Postgrad. Med. J., August 1, 2008; 84(994): 403 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Varghese, M. Burness, H. Xu, T. Beresnev, J. Pingpank, and H. R. Alexander Site-Specific Gene Expression Profiles and Novel Molecular Prognostic Factors in Patients with Lower Gastrointestinal Adenocarcinoma Diffusely Metastatic to Liver or Peritoneum Ann. Surg. Oncol., December 1, 2007; 14(12): 3460 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Graesslin, A. Cortez, R. Fauvet, M. Lorenzato, P. Birembaut, and E. Darai Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study Ann. Onc., April 1, 2006; 17(4): 637 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-J. Oh, J. L. Martin, A. J. Williams, R. E. Peck, C. Pokorny, P. Russell, D. E. Birk, and D. J. Rhee Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 953 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lyall, S. R. Dundas, S. Curran, and G. I. Murray Profiling Markers of Prognosis in Colorectal Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1184 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Gerlach, J. E. Tanus-Santos, and P. Vihinen Circulating Matrix Metalloproteinase-9 Levels as a Biomarker of Disease Clin. Cancer Res., December 15, 2005; 11(24): 8887 - 8888. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
